A Phase I, First Time in Human, Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Anti-Her3 Monoclonal Antibody GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2017
At a glance
- Drugs GSK 2849330 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 03 Aug 2017 Planned End Date changed from 1 Aug 2017 to 29 Sep 2017.
- 03 Aug 2017 Planned primary completion date changed from 1 May 2017 to 29 Sep 2017.
- 27 Apr 2017 Planned End Date changed from 1 May 2017 to 1 Aug 2017.